Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.67
+2.7%		$1.09
$0.16
▼
$2.54
$162.26M0.7422.65 million shs6.36 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
0.00%+3.35%-31.47%-14.19%-25.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.67
+2.7%		$1.09
$0.16
▼
$2.54
$162.26M0.7422.65 million shs6.36 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
0.00%+3.35%-31.47%-14.19%-25.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.20
Hold$5.20680.20% Upside

Current Analyst Ratings Breakdown

Latest OTLK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
8/12/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/28/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/27/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$1.60
7/27/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$4.00
6/24/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/11/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$6.00 ➝ $10.00
(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$1.35M120.19N/AN/A($0.04) per share-16.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$62.42M-$0.77N/AN/AN/AN/AN/A-254.82%N/A

Latest OTLK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q3 2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.08-$0.09-$0.01-$0.15$0.97 million$0.01 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.81
0.63

Institutional Ownership

CompanyInstitutional Ownership
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%

Insider Ownership

CompanyInsider Ownership
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
20243.45 million239.07 millionOptionable

Recent News About These Companies

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352397/0/en/outlook-therapeutics-appoints-kevin-lundquist-as-chief-financial-officer-as-it-prepares-for-u-s-commercial-launch-of-lytenava.html
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352076/0/en/outlook-therapeutics-ceo-bob-jahr-participates-in-the-virtual-investor-why-now-on-demand-conference.html
Analysts Issue Forecasts for Oncobiologics FY2026 Earnings
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analysts-issue-forecasts-for-oncobiologics-fy2026-earnings-2026-08-21/
Brookline Capital Markets Comments on Oncobiologics Q1 Earnings
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brookline-capital-markets-comments-on-oncobiologics-q1-earnings-2026-08-20/
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975675/otlk-q3-earnings-call-maps-lytenava-u-s-launch-and-sales-ramp?cid=cs-stocknewsapi-ft-analyst_blog_plus|earnings_call_takeaways-2975675
Short Interest in Oncobiologics, Inc. (NASDAQ:OTLK) Grows By 78.0%
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-oncobiologics-inc-nasdaqotlk-grows-by-780-2026-08-17/
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
August 15, 2026  |  defenseworld.netD
Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-08-15/
Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Brokerages
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-inc-nasdaqotlk-given-average-rating-of-hold-by-brokerages-2026-08-15/
Oncobiologics (NASDAQ:OTLK) Downgraded to "Sell" Rating by Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-downgraded-to-sell-rating-by-wall-street-zen-2026-08-15/
Oncobiologics (NASDAQ:OTLK) Director Ghiath Sukhtian Buys 2,525,252 Shares of Stock
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-director-ghiath-sukhtian-buys-2525252-shares-of-stock-2026-08-14/
Oncobiologics (NASDAQ:OTLK) Releases Earnings Results
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-releases-earnings-results-2026-08-14/
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936801-outlook-therapeutics-inc-otlk-q3-2026-earnings-call-transcript
Oncobiologics' (OTLK) Buy Rating Reaffirmed at BTIG Research
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-otlk-buy-rating-reaffirmed-at-btig-research-2026-08-14/
Oncobiologics Q3 Earnings Call Highlights
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-q3-earnings-call-highlights-2026-08-14/
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2974790/outlook-therapeutics-inc-otlk-reports-q3-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2974790
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345250/0/en/outlook-therapeutics-reports-third-quarter-fiscal-year-2026-financial-results-and-provides-business-update-highlighting-fda-approval-of-lytenava.html
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
August 14, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61200760/outlook-therapeutics-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts?utm_source=snapi
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344189/0/en/outlook-therapeutics-announces-pricing-of-55-0-million-public-offering-of-common-stock-and-warrants.html
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972032/otlk-up-more-than-300-in-3-months-here-s-what-you-should-know?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-2972032
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970019/outlook-therapeutics-inc-otlk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_9-2970019

New MarketBeat Followers Over Time

Media Sentiment Over Time

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.67 +0.02 (+2.70%)
As of 09/4/2026 04:00 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas